Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50p -5.68% 41.50p 41.00p 42.00p 44.00p 41.50p 44.00p 138,828 12:36:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 31.05

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
22/8/201721:09ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET7,302
16/3/201720:00ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE."3,646
08/10/201612:43Angle PLC 201130,115
02/12/201513:04Angle 2016 – Liquid Biopsy Takeover Target-
11/6/201508:16MrKeysersoze39

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-08-22 14:44:4441.081,750718.90O
2017-08-22 14:37:3641.008,0003,280.00O
2017-08-22 14:22:0241.1013,7745,661.11O
2017-08-22 13:57:4341.93500209.65O
2017-08-22 12:33:4242.0025,00010,500.00OK
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

DateSubject
22/8/2017
09:20
Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 44p.
Angle Plc has a 4 week average price of 41.25p and a 12 week average price of 41.25p.
The 1 year high share price is 80p while the 1 year low share price is currently 41.25p.
There are currently 74,815,774 shares in issue and the average daily traded volume is 51,967 shares. The market capitalisation of Angle Plc is £31,048,546.21.
01/8/2017
16:52
glasswala: It's frustrating to see the share price get smashed after the results of the trials. This is mainly the management's fault in not addressing the funding impasse as well as managing expectations. We all know that they require funds for further trials and Working Capital and it would have been better to have raised this when the share price was in the 70's but I think the results of trials were not as they had hoped and that's why they was no fund raising going as there was nothing to get the investing community interested in making an investment. The FDA submissions are further delayed and there was no enthusiasm in respect of additional machine or cassette sales. All an all a disappointing 6month with additional losses. Management is too top heavy and costs needs to be controlled especially management remuneration which are far too excessive for the set up.
28/7/2017
09:01
life guard: Problem we have is loads of potential but low on sales. I thought pod cast was poor nothing we did not know.. The treated AN promised has occurred but the wrong way. Results promised for breast canctnow put back 6 months Now funds need replenishing and share price falling Finally there is talk of partnership which if can occur will be great No funding mentioned yet which o am surprised about it goes against the grain.. My hope is there is some unexpected news that boosts the share price and that is what AN is waiting for This is a high possibility with all the potential Parsortix has to offer. I am depressed the value of this co has fallen however I know that Parsortix will with its medical uniqness will succeed this may be with or without AN..so I calmly wait without concern of my investment.
14/6/2017
13:01
maddox: Having invested in the biotech sector over the years - I have never previously seen such outstandingly good trial results as AGL has produced. However, IMHO this is not reflected in the share price and I don't think more good results will have a markedly different market response. It is commercialization news that we need to move the share price out of its current range. Regards Maddox
11/6/2017
15:55
alloa2003: Personally I think if AGL had taken this slowly slowly approach a couple of years ago the share price would be much higher. We have suffered from mismanagement of expectations but hopefully the BOD have learnt a lesson. Let the results come through and let them speak for themselves. Trying to guess when the FDA might act on AGL's application(s) is a waste of time but good trial results will put more pressure on the FDA. Share price targets of £5 are unrealistic at this moment in time but we could have a game changing year and a rejuvenated share price. First of all we need to see constant positive news flow and better management of expectations. The recent research note suggesting a share price of 187p (from memory) seems ambitious but achievable in this very volatile area in which AGL operates. One of the other keys is to maximise the current benefits of Parsortix over competing system asap - that way we get a foothold in the market. Once we are there, the companies who operate in this area will not be changing their systems every 2 minutes and only then will we see the sales flow that everyone has been hoping for.
30/3/2017
09:20
alloa2003: Personally I think we will get there in the end but I have to laugh when people ignore what the market is telling us with the share price. If the shares were £1.20 everyone would be saying the price reflects the potential but some how when the shares are 44p the market has got it all wrong. Short term weakness in the share price should spur the management to getting more focused. This is not just any old product this is a life saver if we put aside the potential for the share price for one moment, this can save lives.
22/1/2017
21:05
fraybentos2: what is fair value for agl tiny revenues many competitors board of directors underperforming ctcs will not in the long term be used for cancer detection there is no proof of the value of ctcs for any other purpose no fda approval this year machine not fully automated delays in trials starting further dilution required absent deal lack of market confidence given revenues slow prospects and the above difficulties £10m perhaps on a good day so without a deal or pumped share price agl is worthless dilution required will be too high to make investable good news for mug punters the share price is higher than it should be bad news for mug punters the share price is falling
20/12/2016
18:51
adorling: At least those greedy Directors will need to get the share price to 129p before they can exercise those options granted in November! "The exercise price for the new share options is 64.50 pence per share, representing the Company's closing mid-market share price on 25 November 2016, being the latest practicable date prior to this announcement. The options are subject to service and/or performance conditions. The new share options granted to the executive directors have a term of ten years and are subject to the performance condition that the share price has risen by at least 100% from the share price when the option is issued."
10/12/2016
18:23
m5: Elbillo8 Dec '16 - 20:33 - 4518 of 4553 No disrespect, ignoring a share price because you have faith in the Company can be a dangerous game IMHO. Are you saying that if the share price dropped to 30p you would be still comfortable? It is rare that the market gets it consistently wrong. At the end of the day the only thing that does matter is the share price I do not see anything with the share price at the moment that causes concern as the share price is trading within its range, however should it move outside of that range I would be paying attention, that applies to both the upper and lower levels. I would say flexibility in any share is the key, if you sell you can always buy back. I wish all holders the best of luck.
28/11/2016
07:17
gary38: Angle PLC ISSUE OF SHARE OPTIONSSource: UK Regulatory (RNS & others)TIDMAGLRNS Number : 2366QAngle PLC28 November 2016 For immediate release 28 November 2016 ANGLE plc("ANGLE" or the "Company")ISSUE OF SHARE OPTIONSANGLE plc (AIM: AGL; OTCQX: ANPCY), the specialist medtech company, announces that under the shareholder approved Remuneration Policy the Remuneration Committee has approved the issue of 1,500,000 share options to the Company's executive directors. The Remuneration Committee has also approved the issue of 1,805,000 share options to certain staff.Following the issue of these share options, the Company will have outstanding options over a total of 10,365,806 ordinary shares of GBP0.10, representing approximately 11.6% of its issued and to be issued share capital. This leaves approximately 3.9 million options unallocated within the approved limit of up to 16% of the issued and to be issued share capital from time to time.The exercise price for the new share options is 64.50 pence per share, representing the Company's closing mid-market share price on 25 November 2016, being the latest practicable date prior to this announcement. The options are subject to service and/or performance conditions.The new share options granted to the executive directors have a term of ten years and are subject to the performance condition that the share price has risen by at least 100% from the share price when the option is issued.Following the issue of the new share options, the total number of share options held by the executive directors of the Company will be:
04/11/2016
00:42
escapetohome: Perhaps how netsci performs tomorrow on the fda news and the other news CE MARK will give somewhat of a tiny flavour of what agl share price will do on fda news. I know netsci not full fda , thts why i said small flavour !
Angle share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170823 00:29:08